Summary Interleukin-2 (IL-2) is a critical cytokine for T cell peripheral tolerance and
immunity. Here, we review how IL-2 interaction with the high-affinity IL-2 receptor (IL-2R) …

Highlights•Evidence that PD-1/PD-L1 blockade benefits patients with ovarian cancer
lacks.•Mechanisms by which ovarian cancer resists PD-1/PD-L1 blockade are increasingly …

Proinflammatory cytokines have been approved by the Food and Drug Administration for the
treatment of metastatic melanoma and renal carcinoma. However, effective cytokine therapy …

CD8+ T cell immune responses are regulated by multi-layer networks, while the post-
translational regulation remains largely unknown. Transmembrane ectodomain shedding is …

BRCA1-mediated homologous recombination is an important DNA repair mechanism that is
the target of FDA-approved PARP inhibitors, yet details of BRCA1-mediated functions …

Immunotherapies have revolutionized the treatment of a variety of cancers. Epithelial
ovarian cancer is the most lethal gynecologic malignancy, and the rate of advanced tumor …

The implementation of cancer immunotherapies has seen limited clinical success in head
and neck squamous cell carcinoma (HNSCC). Interleukin-2 (IL-2), which modulates the …

Regulatory T (Treg) cells play a key role in maintaining immune tolerance and tissue
homeostasis. However, in some disease microenvironments, Treg cells exhibit fragility …

Neoadjuvant immunotherapy with anti-cytotoxic T lymphocyte–associated protein 4
(CTLA4)+ anti–programmed cell death protein 1 (PD1) monoclonal antibodies has …

Combination of radiation therapy (RT) with immune checkpoint blockade can enhance
systemic anti-tumor T cell responses. Here, using two mouse tumor models, we demonstrate …